海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
15件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- The research study for patients with Alzheimer's disease to examine the safety and efficacy of Pimavanserin for the treatment of symptoms of agitation and aggression
- Agitation and Aggression in Alzheimer's Disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Chile, France, Germany, Spain, United Kingdom, United States
- 2016-12-27
Authorised
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER’S DISEASE
- Alzheimer’s Disease (AD) MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-05-26
Authorised
- An Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease
- Alzheimer’s Disease MedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Estonia, France, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Democratic People's Republic of, Mexico, Netherlands, Norway, Peru, Poland, Portugal, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, Turkey, United Kingdom, United States
- 2017-01-03
Authorised
- This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study. The efficacy and safety of investigated drug RVT-101 at a dose of 35 mg daily when used as an adjunct treatment to stable donepezil therapy will be evaluated over a 24-week treatment period for mild to moderate Alzheimer’s disease in patients on stable therapy with donepezil.
- Alzheimer’s Disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Bulgaria, Canada, Chile, Croatia, Czech Republic, France, Germany, Italy, Korea, Republic of, Malaysia, Poland, Serbia, Singapore, Slovakia, Spain, United Kingdom, United States
- 2015-11-11
Authorised
- DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER?S DISEASE
- Alzheimer?s Disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Australia, Austria, Belgium, Bulgaria, Canada, Costa Rica, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Poland, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2016-05-17
